Literature DB >> 11753559

Charcoal hemofiltration for hepatic veno-occlusive disease after hematopoietic stem cell transplantation.

A Tefferi1, S Kumar, R C Wolf, M Q Lacy, D J Inwards, J M Gloor, R C Albright, P S Kamath, M R Litzow.   

Abstract

Hepatic veno-occlusive disease (HVOD) after hematopoietic stem cell transplantation (HSCT) results in considerable morbidity and mortality. No therapy has been shown to be uniformly effective. Several studies have highlighted the pivotal role of endothelial injury and the hemostatic system in the pathogenesis of HVOD. Charcoal hemofiltration has been shown to be effective for adsorbing circulating bilirubin and other protein-bound toxins and for supporting patients in hepatic failure. We describe two adult patients with severe, biopsy-proven HVOD (peak bilirubin levels, more than 50 mg/dl in both cases) after HSCT who were successfully treated with charcoal hemofiltration after other treatments failed (including defibrotide in one patient). Both patients were heavily treated before they underwent either autologous (melphalan and total body irradiation conditioning) or allogeneic (cyclophosphamide and total body irradiation conditioning) HSCT. Additional studies are warranted to confirm this preliminary observation and investigate the mechanism of action.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11753559     DOI: 10.1038/sj.bmt.1703267

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  3 in total

Review 1.  Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: Prophylaxis and treatment controversies.

Authors:  Daniel Kl Cheuk
Journal:  World J Transplant       Date:  2012-04-24

2.  A case report of hepatic veno-occlusive disease after ingesting dainties.

Authors:  Yong-Song Guan
Journal:  World J Gastroenterol       Date:  2006-11-07       Impact factor: 5.742

Review 3.  Hepatic venous outflow obstruction: three similar syndromes.

Authors:  Ulas-Darda Bayraktar; Soley Seren; Yusuf Bayraktar
Journal:  World J Gastroenterol       Date:  2007-04-07       Impact factor: 5.742

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.